2023
Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemIntegrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results
MacLean R, Heapy A, Waters A, Wolkowicz N, Szollosy S, Meyerovich J, Sofuoglu M. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. Drug And Alcohol Dependence 2023, 246: 109857. PMID: 37004461, PMCID: PMC10189744, DOI: 10.1016/j.drugalcdep.2023.109857.Peer-Reviewed Original ResearchConceptsTrial-level bias scoresOpioid cuesAB taskCognitive bias modification taskAttentional bias taskCognitive bias modificationComputer-based tasksPreliminary efficacyOpioid use disorderCurrent studyBias modificationBias taskBias scoresModification tasksCBM groupCBM tasksChronic painAcceptability measuresControl conditionTaskUse disordersClinical careCuesTime interactionParticipantsOpioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use
MacLean RR, Sofuoglu M, Stefanovics E, Rosenheck R. Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use. Psychological Services 2023, 20: 157-165. PMID: 34968125, PMCID: PMC9358616, DOI: 10.1037/ser0000607.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidChronic PainCost of IllnessDelivery of Health CareHumansOpioid-Related DisordersVeteransConceptsOpioid use disorderChronic painMental health diagnosesService useUse disordersHealth AdministrationConcurrent opioid use disorderHealth diagnosisOngoing opioid epidemicOutpatient service useVeterans Health AdministrationMental health disordersSubstance use diagnosesSingle disorder groupsClinical service useOpioid prescriptionsAdditional comorbiditiesMultinomial regression analysisDisease burdenMedication fillsOpioid epidemicPrescription opiatesMedical conditionsMedical disordersUse diagnoses
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liability
2021
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchMeSH KeywordsAcute PainAnalgesiaAnalgesics, OpioidBuprenorphineFemaleHumansMaleMethadoneOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy personsThe Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNarcotic AntagonistsOpioid-Related DisordersReceptors, Opioid, muSubstance Withdrawal SyndromeConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trials
2019
Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients
Arout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 2018, 236: 2857-2866. PMID: 30564869, PMCID: PMC6581631, DOI: 10.1007/s00213-018-5146-7.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaCold pressor testOpioid use disorderSerum cytokinesPain thresholdUse disordersAddiction-related outcomesProinflammatory serum cytokinesActivation of microgliaSeverity of painEcological momentary assessmentEnd of treatmentHuman laboratory studiesTest sessionsOpioid cravingMinocycline treatmentOpioid toleranceAgonist treatmentPain sensitivityVisit 1Minocycline effectsPressor testExperimental painPreclinical studiesGo/No-Go taskThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAnalgesics, OpioidAnimalsCholinergic AgentsHumansNon-Neuronal Cholinergic SystemOpioid-Related DisordersConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2015
Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations
Arout CA, Edens E, Petrakis IL, Sofuoglu M. Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations. CNS Drugs 2015, 29: 465-486. PMID: 26142224, DOI: 10.1007/s40263-015-0255-x.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaClinical treatmentChronic painEfficacious treatment regimenTreatment of painOpioid-dependent individualsOpioid-related overdosesAminobutyric acid receptorsDeleterious profileProspective adjuvantOpioid prescriptionsSevere painOpioid analgesicsTreatment regimenNeuroimmune systemPainful stimuliSide effectsLong-term exposurePainAcid receptorsOpioidsClinical usePotential modulatorsHyperalgesiaParadoxical state